Clinical trials: Age Related Maculopathy
Age Related Macular Degeneration, Diabetic Macular Edema
Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab
Objective: To determine the association between baseline aqueous cytokine levels and treatment intervals for patients under a variable dosing regimen with intravitreal ranibizumab in patients with neovascular age-related macular…
- Conditions
- Age Related Macular Degeneration, Diabetic Macular Edema, Macular Edema, Retinal Vein Occlusion
- Trial name
- COVERT (NCT03056092)
- Testing
- Intravitreal ranibizumab
- Where
- 2 sites in Canada
- Volunteers
- 168 people
- Sponsor
- Unity Health Toronto
Neovascular Age-related Macular Degeneration
Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration
This phase II study was designed to evaluate the safety, tolerability, and efficacy of bevacizumab treatment in conjunction with PDT at the low fluence rate compared with bevacizumab alone or combined with PDT at the standard…
- Trial name
- ARMAST (NCT00696592)
- Testing
- Bevacizumab (Avastin), Verteporfin (Visudyne)
- Where
- Italy
- Sponsor
- University of Padova
Wet Age-related Macular Degeneration
A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of QL1207 compared to Eylea® in subjects with wet AMD.
- Trial name
- NCT05345236
- Testing
- Aflibercept
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Subfoveal Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization…
- Trial name
- NCT01122511
- Testing
- 700 ug dexamethasone, ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Allergan
Wet Age-related Macular Degeneration
A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)
This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of JL14002 compared to Lucentis® in subjects with wAMD.
- Trial name
- NCT07389577
- Testing
- JL14002 monoclonal antibody(Fixed dosing regimen), Ranibizumab(Fixed dosing regimen), JL14002 monoclonal antibody(PRN)
- Where
- China
- Volunteers
- 443 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Neovascular Age-related Macular Degeneration
A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).
In people with neovascular age-related macular degeneration (nAMD), the body makes too much of a protein called vascular endothelial growth factor (VEGF).
- Trial name
- BELUGA (NCT04641234)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Belgium
- Volunteers
- 330 people
- Sponsor
- Bayer
Age Related Macular Degeneration
Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy
The rationale for evaluating LucentisTM (a recombinant humanized anti-human Vascular Endothelial Growth Factor (VEGF) monoclonal antibody (Fab) in patients with neovascular (wet) Age related Macular Degeneration (AMD) is based on…
- Trial name
- FVF4193s (NCT01255774)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The New York Eye & Ear Infirmary
Exudative Age-related Macular Degeneration
A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration
This is a multicenter, active-controlled, double masked study assessing the safety, efficacy and durability of four monthly intravitreal (IVT) injections of RBM-007 monotherapy, and four monthly RBM-007 injections in combination…
- Trial name
- TOFU (NCT04200248)
- Testing
- RBM-007 Injectable Solution, Aflibercept
- Where
- 8 sites in United States
- Volunteers
- 94 people
- Sponsor
- Ribomic USA Inc
Macular Degeneration, Choroidal Neovascularization
Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease
The purpose of this study is to determine the safety and tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in patients with late stage Age-Related Macular Disease (AMD).
- Trial name
- NCT00102115
- Testing
- Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Light Sciences LLC
Age Related Macular Degeneration
Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
The investigators hope to determine if "wet" AMD patients differ from patients with "dry" AMD or normal eyes in the production of anti-retinal pigment epithelium (anti-RPE) or anti-retinal antibody formation.
- Trial name
- Antibody (NCT00931489)
- Testing
- ranibizumab (Lucentis(R))
- Where
- United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Lawrence S. Morse, MD
Age Related Macular Degeneration
Usability of the Foresee Home in Intermediate Age Related Macular Degeneration (AMD) Patients
The study purpose is to demonstrate that the target population can receive a packed FORESEE HOME unpack it, install and operate it to an extent that the FORESEE HOME can monitor them for changes in the visual field with good…
- Trial name
- UU2 (NCT00748384)
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Notal Vision Ltd.
Age Related Macular Degeneration
Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
The purpose of this study is to demonstrate that Visudyne-Lucentis-dexamethasone (V-L-D) triple therapy will give similar efficacy and safety results as Lucentis monotherapy.
- Trial name
- NCT00457678
- Testing
- Visudyne, Lucentis, Dexamethasone
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Age Related Macular Degeneration
Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD
This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HLX04-O administered every 4 weeks in participants with wet age-related macular degeneration (wAMD)
- Trial name
- NCT04993352
- Testing
- recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Henlius Biotech
Wet Macular Degeneration
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments.
- Trial name
- STAR (NCT01243086)
- Testing
- Ranibizumab, OZURDEX
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McMaster University
Dry AMD, Geographic Atrophy
Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence.
- Conditions
- Dry AMD, Geographic Atrophy, Healhty
- Trial name
- VIRETTA (NCT07433088)
- Testing
- Object recognition and selection task
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Streetlab
Age Related Macular Degeneration
Non-invasive Optical Angiography in Age-related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of severe and irreversible visual loss and classified blindness in the elderly throughout Europe and the US.
- Trial name
- NCT02521142
- Testing
- Non-invasive OCT based optical angiography, Oxymap T1, OCT
- Where
- Austria
- Volunteers
- 72 people
- Sponsor
- Medical University of Vienna
Age-related Macular Degeneration (AMD)
Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place
Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for "straight-ahead" activities such as reading, sewing, and driving.
- Trial name
- DEMELE (NCT03690505)
- Testing
- Interviews
- Where
- France
- Volunteers
- 118 people
- Sponsor
- University Hospital, Limoges
Maculopathy, Age-Related
Treatment of Patients With Neovascular AMD Using Indocyanine Green-Mediated Photothrombosis (i-MP).
To establish the safety and efficacy of indocyanine green-mediated photothrombosis (i-MP) for the treatment of patients with neovascular age-related macular degeneration.
- Trial name
- NCT00331253
- Testing
- Indocyanine Green-Mediated Photothrombosis
- Where
- Brazil
- Volunteers
- 280 people
- Sponsor
- Opto Eletronica S.A.
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT03834753
- Testing
- bevacizumab, ranibizumab
- Where
- 50 sites in United States
- Volunteers
- 228 people
- Sponsor
- Outlook Therapeutics, Inc.
Dry Age-related Macular Degeneration, Geographic Atrophy
First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration
The study is designed to identify the maximum tolerated dose (MTD) for intravitreal (IVT) administration of GEM103 in subjects with geographic atrophy (GA) secondary to dry AMD.
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease
- Trial name
- NCT04246866
- Testing
- GEM103
- Where
- 12 sites in United States
- Volunteers
- 12 people
- Sponsor
- Gemini Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.